PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

The three sections of Figure 22 follow the development of the combined Novartis and BMSportfolio on Atazanavir. The top section of the table shows that the portfolio includesgranted patents and also pending applications that were filed since 2002. The inventionsfound by chemical searching were filed beginning in 1995, but the clinically-orientedcollection begins in 1999, with the Atazanavir name per se appearing in 2001. From thebeginning, in 1995, utility for treatment of HIV was claimed, and Atazanavir was of course,not the first composition in this drug class, with multiple predecessors in the class, led byRoche’s Saquinavir that had was approved by the FDA in 1995, and which is now offpatent.The mid-section of the table reviews the different aspects of drug development mentionedin patents in the Novartis-BMS portfolio. Use of the drug in combination was included in thefounder patent, since much had already been learned about combination treatment of HIVby 1995. <strong>Patent</strong>ing of synthetic approaches persists over the entire time frame, andformulation patents are noted starting in 1998. Specific combinations begin to appear in1998, and combinations addressing both the same (PI) and different targets are mentioned,with the latest being viral fusion inhibitors.Figure 22. Timelines for Atazanavir Development CategoriesThe last section of the table deals with clinical indications other than HIV infection, andthese were not filed until after approval for the HIV indication was received.28
Several of the representative patents held by Novartis and Bristol-Myers Squibb are listedin Figure 23. A list of all the ATZ patents in the collection that are held by Novartis/BMS isprovided in an Appendix.Figure 23 Representative <strong>Patent</strong>s from Novartis and Bristol-Myers Squibb29
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29: THE DEVELOPER’S OWN TIMELINEThe A
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35 and 36: PATENT QUALITY INDICATORS FOR SELEC
Page 37 and 38: Figure 30. References made by the F
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?